



PCT/EP2004/005563

22 07 2004



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 06 AUG 2004

WIPO PCT

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

R. Mahoney
20 July 2004

Best Available Copy

THE PATENT OFFICE

H

20 AUG 2003

NEWPORT

Request for grant of a patent*(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

C139.009.01

2. Patent application number

(The Patent Office will fill in this part)

0319514.6

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)Cellpep S.A.
16 rue de la Banque
75002 Paris
FrancePatents ADP number (*if you know it*)

7560113002

If the applicant is a corporate body, give the country/state of its incorporation

French

4. Title of the invention

Modified antiviral peptides with increased activity and cell membrane affinity

5. Name of your agent (*if you have one*)"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)SERJEANTS
25 The Crescent
King Street
Leicester
LE1 6RXPatents ADP number (*if you know it*)

1461001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
*(if you know it)*Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
*(day / month / year)*8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

Yes

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)

Patents Form 1/77

9 Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description

18

Claim(s)

2

Abstract

Drawing(s)

JWL

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination
(Patents Form 10/77)

Any other documents

(Please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

SERJEANTS

Serjeants

Date

15 Aug 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Ian E McKelvey
0116 233 2626

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

TITLE

Modified antiviral peptides with increased activity and cell membrane affinity

DESCRIPTION

The invention relates to compounds with increased antiviral activity, in particular increased anti-HIV activity, due to the covalent graft on the original antiviral molecule of a structure capable of cell membrane interaction and/or crossing.

Background

Multiple branch peptide constructions (MBPCs) comprise a core matrix to which small peptides are bonded. The core matrix is a dendritic polymer which is branched in nature, preferably with each of the branches thereof being identical. Although other core molecules are possible, the preferred core molecule is lysine. The core matrix can be built up from a central lysine residue, sometimes called the root of the MBPC. Two lysine residues are bonded to the central lysine residue, each through its carboxyl group to a different one of the amino groups of the central lysine residue. This provides a molecule with four amino groups, which may be the core matrix for an MBPC having four peptides. Alternatively by bonding a further four lysine residues, each through its carboxyl group to a different one of the said four amino groups, one can provide a molecule with eight branches. This molecule can serve as the core matrix for an MBPC having eight peptides or can alternatively receive eight lysine residues in the manner described above to form a core matrix for an MBPC having sixteen peptides. The C-ends of peptides are covalently bonded to each of the branches of the core matrix to form the MBPC. The peptides may be the same, which is preferred, or may be different from one another. The resulting molecule has a cluster of peptides at the surface and an interior core matrix which is not presented and is therefore not antigenic.

Spacers may, if desired, be included between the peptides and the core matrix. The carboxyl group of the first lysine residue may be left free, amidated, or coupled to a blocking compound such as β -alanine (β -aminopropionic acid). Peptides can include D or L-amino acid residues. D amino acids last longer *in vivo* because they are harder for peptidase to cut, but the L amino acids have better activity. Moreover, peptide analogues, synthetic constructs using the carbon skeleton of peptides but omitting the -CONH- peptide bonds, can be employed in place of peptides. Thus, it should be understood that references to peptides

herein may also be taken to include peptide analogues. It is believed that peptide analogues will be more resistant to peptidase and last longer in vivo. If the peptide is too long, the MBPC will become antigenic. It is therefore desirable that each peptide should have not more than ten, and preferably not more than nine, amino acid residues.

MBPCs for use in the treatment of HIV infections were first described by J-M. Sabatier et al in WO 95/07929. The MBPCs described therein have peptides which contain the sequence GPGR (from the V3 loop of the surface envelope glycoprotein gp120 of HIV) preceded by from 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. The amino acid sequences IGPGR and IXXGPGR (where X is an amino acid residue) are excluded. The most preferred of these MBPCs has a lysine residue core with eight peptides GPGRAF bonded thereto. It may be represented as $(GPGRAF)_8\text{-K}_4\text{-K}_2\text{-K-}\beta\text{A-OH}$, the OH terminal indicating the carboxyl group of the β -alanine. That carboxyl group may alternatively be modified to form a carboxamide terminal. This compound is referred to herein as SPC3.

In WO 98/29443, J-M Sabatier et al described further MBPCs which may be effective in the treatment of HIV infection. These use peptides derived from the HIV envelope transmembrane glycoprotein gp41. The peptides contain the sequence RQGY preceded by from 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. The most preferred of these MBPCs has a lysine residue core with eight peptides RQGYSPL bonded thereto. It may be represented as $(RQGYSPL)_8\text{-K}_4\text{-K}_2\text{-K-}\beta\text{A-OH}$, the OH terminal indicating the carboxyl group of the β -alanine. That carboxyl group may alternatively be modified to form a carboxamide terminal. This compound is referred to herein as RL, although it has in the past also been referred to as SPC RL and as RL41.

Subsequently to WO 98/29443, it was established that the MBPC $(RQGYSPL)_2\text{-K-}\beta\text{A}$ (hereinafter RL dimer) is effective but that the MBPC $(RQGYSP)_2\text{-K-}\beta\text{A}$ is less so. This was thought to confirm the lower limit of 6 amino acids in the peptide branches of the MBPCs. However, K Mabrouk et al showed in PCT/EP03/04353 that some shorter peptides could be used, in particular $(RQGYS)_2\text{-K-}\beta\text{A-OH}$ (hereinafter RS, but in the past also referred to as Short RL) and $(RQGY)_8\text{-K}_4\text{-K}_2\text{-K-}\beta\text{A-OH}$.

SPC3 and RL both have 8 branches and are described as octomers. RS has two branches, and is described as a dimer. None of the monomers, that is the linear peptides GPGRAF, RQGYSPL and RQGYS, has ever shown any activity.

Anti HIV agents such as SPC3 and RL have been shown to block the fusion step of retroviral infection through direct interaction with cell membrane receptors; other anti fusion agents such as enfuvirtide and T-1249 (Trimeris Inc) interact directly with the viral envelope glycoproteins. The activity of the latter depends on the structure of such glycoproteins, and therefore on the viral strain. Ultimately, molecules that interfere directly with viral glycoproteins will lead to the selection of resistant strains. On the contrary, molecules which are able to block cell membrane receptors should not lead to viral selection, as all strains will be similarly inhibited.

Cell receptor blocking HIV inhibitors may interact with the surface of such receptors (for instance CxCR4 or CCR5) but also with intra membrane components of said receptors, or even with sub-membrane sites or events.

As an example, SPC3, which is an extremely water-soluble peptide, has an anti HIV activity in vitro on C8166 cultured cells as well as on peripheral blood lymphocytes (PBL) and on macrophages. B de Rougé in WO 99/34777 showed that this activity is increased 5 to 50 times when SPC3 is associated with certain types of liposomes, probably because of better interaction with cell membranes. However, SPC3 is a polymerized peptide of 56 amino-acid residues. Its association with liposomes is difficult and the yield is not perfect, leading to cost increases as well as technical risks. Other means of improving the efficacy of molecules like SPC3 have therefore been sought.

The invention

The invention provides a compound comprising a water soluble antiviral peptide including one of the sequences GPG and RQGY and, bonded to the C-end of the peptide, a terminator which is either (a) an ω -amino-fatty acid having from 4 to 10 carbon atoms and from 0 to 2 carbon-carbon double bonds or (b) a peptidic cell membrane penetrating agent.

The antiviral peptide may be an MBPC with a lysine core matrix. In such a case the terminator is bonded to the root lysine residue. The MBPCs described above may be used, that is to say SPC3 which has 8 branches of GPGRAF, RL which has 8 branches of RQGYSPL and RS which has 2 branches of RQGYS. However, the improvement resulting from the bonding of the terminator to the C-end of the antiviral peptide is so great that SPC3 and RL can be reduced to two branches (SPC3 dimer and RL dimer, respectively), or even to one branch (SPC3 monomer and RL monomer, respectively), while RS may also be reduced to one branch (RS monomer). Further work has even indicated that SPC3 monomer (GPGRAF) may be shortened to GRGRA, GPGR or GPC. As these are much smaller molecules, they are much easier and cheaper to make and are preferred for that reason.

The ω -amino-fatty acid is preferably saturated. Longer chains than 10 carbon atoms are unnecessary as the effect is obtained with less, and longer chains may be too lipidic. The preferred length is from 4 to 8 carbon atoms, and more preferably from 4 to 6 carbon atoms. The most preferred ω -amino-fatty acids are γ -aminobutyric acid, δ -aminovaleric acid and ϵ -aminocaproic acid.

The peptidic cell membrane penetrating agent is suitably a TAT-derived peptide, penetratin® or Kpam, although other peptides may also be suitable.

Experimental

We first synthesized SPC3 octomers, with the graft of saturated fatty acid chains of increasing length, from 4 to 8 carbons, on the core lysine residue; and SPC3 octomers with three different peptide chains on the lysine residue: a TAT-derived peptide, penetratin, and Kpam peptide, all reported to enhance membrane penetration and crossing. We tested the above molecules on C8166 cells infected with NL 4-3 HIV strain, then on PBL with the same strain. Results are shown in Tables 1 and 2.

When positive results were observed, further attempts were made to test whether the graft of membrane affinity chains on the water soluble peptides could allow for a reduction in their size without losing efficacy (SPC3, RL and their derivatives are polymers, often octomers, of small peptides; the monomers have been shown to be inactive), with a view of cost-containment. To this end we synthesized monomers and dimers of the sequences of SPC3, RL

and RS, with the addition of the preferred grafted sequence, and tested them on C8166, PBL and PBMC. Results are shown in Tables 3 to 5.

We also synthesized shortened peptides related to SPC3 monomer, which is GPGRAF, in particular GRGRA, GPGR and GPG and tested these with a δ -aminovaleric acid terminator. These were tested twice, 8 days apart, on C8166 cells against HIV-1 NL 4-3 (results are shown in Tables 6 and 7) and on C8166 cells against HIV-1 NDK (results are shown in Table 8).

Whilst the experiments conducted so far are *in vitro*, it is expected that the modifications made in this invention will lead to better availability of the compounds in the lymphatic system *in vivo*.

Test Methods

Cells and viruses.

HIV-1 NL 4-3 isolate (Adachi et al., 1986; Barré-Sinoussi et al., 1983) and highly cytopathic Zairian HIV-1 NDK isolate (Ellrodt et al., 1984) was propagated in permissive CEM cells (Nara et al., 1987). Uninfected CEM and C8166 (Salahuddin et al., 1983) were maintained in RPMI 1640 (R10) with ultraglutamine (cambrex, Vervier, Belgium), penicillin (100 U/ml), streptomycin (100 μ g/ml), and 10% heat- inactivated fetal calf serum (Cambrex).

Peripheral blood lymphocytes from an HIV-1 negative donor were grown as described earlier, maintained in RPMI 1640 with ultraglutamine, supplemented with IL2 (20 μ g/ml), penicillin (100 U/ml), streptomycin (100 μ g/ml), and 10% heat- inactivated fetal calf serum. Cells were stimulated three days in the medium supplemented with phytohemagglutinin (20 U/ml PHA P, DIFCO, Detroit MI).

HIV-1 infection of C8166 cells

Samples of 3×10^5 /100 μ L C8166 cells were preincubated in 96-well microtiter plates in culture medium containing various concentrations of peptide. After a 1 h treatment at 37°C, 100 μ l of diluted viral solution of HIV-1 was added. The cells were exposed to the virus for 1

h at 37°C at a multiplicity of infection of 1000 TCID₅₀ per ml. The cells were washed three times and cultured at 3 x 10⁵ /ml of R10 with the treatment in 24-well plates incubated at 37°C. C8166 culture medium was replaced at Day-4 post-infection. The treatment was permanent before virus adsorption, during virus adsorption and after infection. Assays on C8166 cells have been performed at least twice and in duplicate. Toxicity was evaluated by daily cell count and trypan-blue exclusion assay. Infection of C8166 T-cells with HIV-1 was assessed by virus-induced cytopathic effects (syncytia formation) and by quantification of cell free p24 viral protein in the culture supernatants. Measurements of HIV-1 p24^{gag} concentration in the culture supernatants were achieved by ELISA (ALLIANCE® HIV-1 p24 kit, Perkin Elmer, life sciences, USA).

Infection of human peripheral blood lymphocytes (PBL)

Samples of 10⁶/100 µL PBL cells were preincubated in 96-well microtiter plates in culture medium containing various concentrations of peptides. After a 1 h treatment at 37°C, 100 µl of diluted viral solution of HIV-1 was added. The cells were exposed to the virus for 1 h at 37°C at a multiplicity of infection of 1000 TCID₅₀ per ml. The cells were washed three times and cultured at 110⁶ /ml of medium with the treatment in 24-well plates incubated at 37° in culture medium with the peptides in 5% CO₂.The treatment was permanent before virus adsorption, during virus adsorption and after infection. The PBL culture medium was replaced every 3-4 days during three weeks always in the presence of peptide. The cell viability was assessed by cell counts and trypan-blue exclusion assay. The viral production in the culture supernatant was quantified by p24 ELISA test, as described earlier. All the experiments have been done in blind-tests. Tests have been done in duplicate.

Results

Table 1

Experiment on C8166 cells with HIV-1NL-4-3

ST	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-TOX	NEG	-TOX	-TOX	-TOX	72
	-TOX	NEG	-TOX	-TOX	-TOX	73
2 µM	-	19	-	-	-	NEG
	-	46	-	-	-	223
1 µM	-	14	(+)	+	+	188
	-	10	-	-	-	169
0.5 µM	-	40	-	+	+	234
	-	45	(+)	+	+	75

Table 1 (continued)

S2	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-TOX -TOX	NEG NEG	-TOX -TOX	TOX TOX	TOX TOX	ND
2 μM	-	NEG NEG	-	-	-	NEG
1 μM	-	NEG NEG	-	-	-	24
0.5 μM	-	NEG NEG	-	-	-	181 245
S3	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-	NEG NEG	-	-	-	28
2 μM	-	NEG NEG	-	-	-	189
1 μM	-	NEG NEG	-	-	-	18 7
0.5 μM	-	15 NEG	-	-	-	9 234
S4	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-	NEG 12	-	-	-	21120
2 μM	-	17 14	-	-	-	15674 17872
1 μM	-	96 244	-	-	-	24806 19801
0.5 μM	-	43 28	-	-	-	21640 19801 25000
S5	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
10 μM	-	NEG NEG	-	-	-	81
5 μM	-	NEG NEG	-	-	-	134
2 μM	-	NEG NEG	-	-	-	66 71
1 μM	-	NEG NEG	-	-	-	206 76
0.5 μM	-	NEG NEG	-	-	-	NEG 152
S6	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
10 μM	-	NEG NEG	-	-	-	NEG
5 μM	-	NEG NEG	-	-	-	NEG
2 μM	-	NEG 8	-	-	-	NEG 67
1 μM	-	12 25	-	(+)	-	164 218
0.5 μM	-	75 14	-	+	-	186 1417 20139
GAZI	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
1 μM	-	NEG NEG	-	-	-	NEG NEG
SPG3	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-	NEG NEG	-	-	-	NEG NEG
2 μM	-	17 6	(+) (+)-	+	++	7589 14787

TCell	-	NEG NEG	-	-	-	NEG NEG
NL4-3 1/1000	(+)	244	+	++	++	25000
	(+)	244	+	++	++	25000

Key

S1: SPC3-(η -aminocaprylic acid)

S4 SPC3-(ϵ -aminocaproic acid)

S2: SPC3-Penetratin

S5: SPC3-(δ -aminovaleric acid)

S3: SPC3-Tat

S6: SPC3-(γ -aminobutyric acid)

++, +, (+), (-) and - represent decreasing numbers of syncitia formed

Table 2

Antiviral Activity Experiment on C8166 cells with HIV NL-4-3

S2	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
1 μ M	-	NEG NEG	-	-	-	67
	-					19
0.5 μ M	-	2 2	- -	- -	+	91 115
0.1 μ M	(+) (+)	75 7	+	+	(+)	596 113
0.05 μ M	(+) (+)	143 28	+	++	++	2923 468
S3	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
1 μ M	-	3	-	-	-	327
	-	1	-	-	-	746
0.5 μ M	-	14 2	- -	- -	(+) +	189 72
0.1 μ M	(+) (+)	61 33	- +	+	++ ++	787 496
0.05 μ M	(+) (+)	261 94	+	++	++	3664 2064
S5	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
1 μ M	-	44	-	-	-	39
	-	18	-	-	(+)	385
0.5 μ M	-	9 58	- -	(+) -	+	39 72
0.1 μ M	(+) (+)	8 73	+	++	++	435 137
0.05 μ M	(+) (+)	66 33	+	++	++	3185 2159
S6	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
1 μ M	-	36	-	-	-	54
	-	17	-	-	-	1668
0.5 μ M	-	14	-	(+)	+	493
	-	54	-	-	+	288
0.1 μ M	(+) (+)	90 14	+	+	++	1957 613
0.05 μ M	(+) (+)	21 303	+	++	++	1271 1022
S7	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
5 μ M	-	NEG NEG	-	+	+	7
	-					105
1 μ M	(+) (+)	44 19	+	++	++	7191 641
AZT	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
1 μ M	-	NEG NEG	-	-	-	1 NEG

Table 2 (continued)

SPC3	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-	NEG NEG	(+) (+)	+	++	288 342
1 μM	(+) (+)	35 11	+	++	++	3943 1297
TCell	-	NEG NEG	-	-	-	NEG NEG
NL4-3 1/1000	(+) (+)	303 184	++ ++	++ ++	++ ++	25000 25000

S1-S6 as above, S7: SPC3-Kpam

++, +, (+), (-) and - represent decreasing numbers of syncitia formed.

All tested analogues showed an increased activity as compared to SPC3 (between 5 and 150 fold).

Similar results were obtained on PBL :

IC ₁₀₀	S1	S2	S3	S4	S5	S6	SPC3
	0.1 μM	0.01 μM	0.1 μM	0.5 μM	0.01 μM	0.01 μM	2 μM

The best agents were S5 and S6, SPC3-(δ-aminovaleric acid) and SPC3-(γ-aminobutyric acid) respectively, with an IC₅₀ of 0.1 to 0.01 μM and no toxicity on cells at doses up to 10μM.

Table 3

Antiviral Activity Experiment on C8166 cells with HIV-1 subtype B NL 4-3

Name	Formula	IC ₅₀ (μM)
SPC3	(GPGRAF) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.5
SPC3 dimer valeric acid	(GPGRAF) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.05
SPC3 monomer	GPGRAF	>10
SPC3 monomer valeric acid	GPGRAF-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.02
RL	(RQGYSPL) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.01
RL dimer	(RQGYSPL) ₂ -K-NHCH ₂ CH ₂ COOH	0.02
RL monomer	RQGYSPL	0.5
RL dimer valeric acid	(RQGYSPL) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.05
RL monomer valeric acid	RQGYSPL-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.05
RS	(RQGYS) ₂ -K-NHCH ₂ CH ₂ COOH	0.1
RS monomer	RQGYS	0.2
RS dimer valeric acid	(RQGYS) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.05
RS monomer valeric acid	RQGYS-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.2

The above table shows that the graft of a valeric acid root on monomers of the peptides RL and SPC3 increases their activity on C8166 cells. In the case of SPC3, the activity becomes greater than that of the original polymerized peptide.

Table 4

Experiment on PBL with NL 4-3 strain

Name	Formula	IC ₅₀ (μM)	IC ₁₀₀ (μM)
SPC3	(GPGRAF) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.01	0.1
SPC3 monomer valeric acid	GPGRAF-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.02	0.1
RL	(RQGYSPL) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.005	0.1
RL dimer	(RQGYSPL) ₂ -K-NHCH ₂ CH ₂ COOH	0.01	0.1
RL dimer valeric acid	(RQGYSPL) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.005	0.05
RL monomer valeric acid	RQGYSPL-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01	1

The results show that monomers or dimers of the original peptides have an activity comparable to that of the octomers. SPC3 monomer valeric acid has an IC₁₀₀ of 0.1 μM, as compared to 2 μM for normal SPC3, and 0.5 μM for SPC3 valeric acid. This is of importance as SPC3 contains 56 amino-acid residues, whereas the monomer contains only 6.

Table 5

Experiment on PBMC with HIV-1 89.6 subtype B dualtropic (X4R5)

Name	Formula	IC ₅₀ (μM)	IC ₁₀₀ (μM)
SPC3	(GPGRAF) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.06	0.5
SPC3 dimer valeric acid	(GPGRAF) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.008	0.5
SPC3 monomer valeric acid	GPGRAF-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01	0.5
RL	(RQGYSPL) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.006	0.05
RL dimer valeric acid	(RQGYSPL) ₂ -K-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01	0.5
RL monomer valeric acid	RQGYSPL-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01	0.1

Table 6

Antiviral Activity Experiment on C8166 cells with HIV NL-4-3

GRPG	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-		-	-	-	1
1 μM	-		-	-	-	5
0.5 μM	-		-	-	-	3.8
0.1 μM	-		-	-	-	5.4
0.05 μM	-		-	(+)	-	7.9
0.01 μM	-		-	(+)	-	18
0.005 μM	-		(+)	(+)	-	525
			(+)	(+)	-	5764
			(+)	(+)	-	7330
			(+)	(+)	-	9810
			(+)	(+)	-	13850
			(+)	(+)	-	11756
			(+)	(+)	-	23810
			(+)	(+)	-	23810
			(+)	(+)	-	23810
GRPG	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
Valeric acid	-		-	-	-	-
5 μM	-		-	-	-	5.6
1 μM	-		-	-	-	3.2
0.5 μM	-		-	-	-	5.636
0.1 μM	-		-	-	-	4.8
0.05 μM	-		-	(+)	-	3.5
0.01 μM	-		-	(+)	-	5.6
0.005 μM	-		-	(+)	-	126
			-	(+)	-	3810
			-	(+)	-	1850
			-	(+)	-	9867
			+	+	-	11810
			+	+	-	13740
			+	++	-	23810
			+	++	-	23810
GRGR	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-		-	-	-	9.425
1 μM	-		-	-	-	3.375
0.5 μM	-		-	-	-	1103
0.1 μM	-		-	-	-	485
0.05 μM	-		(+)	+	-	2507
0.01 μM	-		(+)	+	-	2840
0.005 μM	-		(+)	+	-	5810
			(+)	+	-	10110
			(+)	+	-	2507
			(+)	+	-	13870
			(+)	++	-	23810
			(+)	++	-	23810
			(+)	++	-	23810
			(+)	++	-	23810

Table 6 (continued)

CPGR valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	2.36
1 μM	-		-	-	+	2.4
0.5 μM	-		-	-	+	104
0.1 μM	-		(+)	+	+	179
0.05 μM	-		(+)	+	+	105
0.01 μM	-		(+)	+	+	510
0.005 μM	-		(+)	+	++	433
0.005 μM	-		(+)	+	++	507
0.005 μM	-		(+)	+	++	9840
0.005 μM	-		(+)	+	++	11830
CPGRA valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	3.62
1 μM	-		-	-	-	13
0.5 μM	-		-	-	-	2.9
0.1 μM	-		(+)	+	+	3.2
0.05 μM	-		(+)	+	+	2.1
0.01 μM	-		(+)	+	++	2.1
0.005 μM	-		(+)	+	+	2838
0.005 μM	-		(+)	+	+	2435
0.005 μM	-		(+)	+	++	4230
0.005 μM	-		(+)	+	++	8910
0.005 μM	-		+	++	++/T	15650
0.005 μM	-		+	++	++/T	16810
CPGRA valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	2.7
1 μM	-		-	-	-	1.8
0.5 μM	-		-	-	-	2.3
0.1 μM	-		(+)	+	+	1.9
0.05 μM	-		(+)	+	+	2
0.01 μM	-		(+)	+	+	2.2
0.005 μM	-		(+)	+	+	2352
0.005 μM	-		(+)	+	+	1011
0.005 μM	-		(+)	+	+	6830
0.005 μM	-		(+)	+	+	3820
0.005 μM	-		+	++	++	13030
0.005 μM	-		+	++	++	13810
0.005 μM	-		+	++	++/T	23810
0.005 μM	-		+	++	++/T	23810

Table 6 (continued)

SPC3 monomer of valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	3
1 μM	-		-	-	(+)	3
0.5 μM	-		-	(+)	(+)	325 445
0.1 μM	-		-	(+)	+	1840 2830
0.05 μM	-		(+)	+	++	11810 1507
0.01 μM	-		+	++	++	3810
0.005 μM	-		+	++	++/T	21810
			+	++	++/T	21810
			+	++	++/T	23810
			+	++	++/T	23810
SPC3	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	3
1 μM	-		-	-	(+)	3
0.5 μM	-		-	-	(+)	1692 776
0.1 μM	-		-	(+)	+	5173
0.05 μM	-		(+)	+	++	4840
0.01 μM	-		(+)	++	++	17810
0.005 μM	-		+	++	++/T	19850
			+	++	++/T	23810
			+	++	++/T	23810
			+	++	++/T	23810
			+	++	++/T	23810
TCell	-		-	-	-	3
NL4-3 1/1000	(+) (+)		+	++	++/T ++/T	23810 23810

Table 7

Antiviral Activity Experiment on C8166 cells with HIV NL-4-3

CPG	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-		-	-	-	2
1 μM	-		-	-	(+)	79
0.5 μM	-		-	-	(+)	42 62
0.1 μM	-		-	-	(+)	126 165
0.5 μM	-		-	(+)	+	807
0.01 μM	(+) (+)		(+) (+)	(+)	+	1506 1810 3810
			(+)	+	++	9810
			(+)	+	++	15810

Table 7 (continued)

Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM Valeric acid	-	-	-	-	60 34
1 μM	-	-	-	-	86 74
0.5 μM	-	-	-	(+) (+)	126 44
0.1 μM	-	-	(+)	+	108
0.05 μM	-	-	(+)	+	130
0.01 μM	-	(+) (+)	+	++ ++	3810 2300
GPGR Valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7
5 μM	-	-	-	(+) (+)	152 152
1 μM	-	-	-	(+) (+)	316 343
0.5 μM	-	-	-	+	23000
0.1 μM	-	(+) (+)	+	+	15810 5810
0.05 μM	(+) (+)	+	+	++ ++	13810 23000
0.01 μM	(+) (+)	+	++	++ ++	12980 23810 23810
GPGR Valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7
5 μM	-	-	-	-	-
1 μM	-	-	-	-	-
0.5 μM	-	-	-	+	2740
0.1 μM	-	(+) (+)	+	+	2840 2173
0.05 μM	-	(+) (+)	+	++	9810 9860
0.01 μM	-	+	++	++/T ++	17800 3800 21300
GPGR Valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7
5 μM	-	-	-	(+)	99
1 μM	-	-	-	(+)	100
0.5 μM	-	-	-	(+) (+)	117 119
0.1 μM	-	(+) (+)	+	+	2070 5410
0.05 μM	-	(+) (+)	+	++	2837 9310
0.01 μM	-	+	++	++/T ++/T	4230 8910 15650 16810

Table 7 (continued)

GPGR valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-		-	-	-	2.7
1 μM	-		-	-	-	3
0.5 μM	-		-	-	-	13
0.1 μM	-		-	-	(+)	10
0.05 μM	-		-	(+)	(+)	234
0.01 μM	-		(+)	(+)	(+)	576
0.005 μM	-		(+)	+	+	2356
0.001 μM	-		(+)	+	+	2416
0.0005 μM	-		+	+	+	3810
0.0001 μM	-		+	++	++	11820
0.00005 μM	-		+	++	++	13870
0.00001 μM	-		-	-	-	11810

TCell	-	-	-	-	-	-	2
NL4-3 1/1000	(+)		+	++	++	++/T	6
	(+)		+	++	++	++/T	23810
						++/T	15670
						++/T	19750

Table 8

Antiviral Activity Experiment on C8166 cells with HIV 1 NDK

GPGR valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-		-	-	+	2733
1 μM	-		(+)	+	+	2400
0.5 μM	-		(+)	+	+	2507
0.1 μM	-		+	++	++	3810
0.05 μM	-		+	++	++	21110
0.01 μM	(+)		+	++	++	23810
0.005 μM	(+)		+	++	++	23810
0.001 μM	+		+	++	++	23810
0.0005 μM	+		+	++	++	23810
0.0001 μM	+		+	++	++	23810
0.00005 μM	+		+	++	++	23810
GPGR valeric acid	Day 4	P24 (pg/ml)	Day 5	Day 6	Day 7	P24 (pg/ml)
5 μM	-		-	-	(+)	284
1 μM	-		-	-	(+)	217
0.5 μM	-		-	-	+	2810
0.1 μM	-		-	+	++	1840
0.05 μM	-		-	+	++	2578
0.01 μM	-		-	+	++	3140
0.005 μM	-		-	+	++	3507
0.001 μM	-		(+)	++	++	3670
0.0005 μM	-		(+)	++	++	11810
0.0001 μM	(+)		+	++	++	15879
0.00005 μM	(+)		+	++	++	23810
0.00001 μM	(+)		+	++	++	23810
0.000005 μM	(+)		+	++	++	23810

Table 8 (continued)

CPGR	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
5 μM	-		-	+	++	2840
1 μM	-		-	+	++	7810
0.5 μM	-		(+)	++	++	9870
0.1 μM	-		(+)	++	++	13890
0.05 μM	-		(+)	++	++	9810
0.01 μM	-		(+)	++	++	15856
0.005 μM	-		(+)	++	++	21810
0.001 μM	-		(+)	++	++	23870
0.0005 μM	-		(+)	++	++	23810
0.0001 μM	-		(+)	++	++	23810
0.00005 μM	-		(+)	++	++	23810
CPGR valeric acid	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
5 μM	-		-	(+)	+	3810
1 μM	-		-	(+)	+	3810
0.5 μM	-		-	+	++	2840
0.1 μM	-		-	+	++	3810
0.05 μM	-		-	+	++	7810
0.01 μM	-		(+)	++	++	3840
0.005 μM	-		(+)	++	++	17890
0.001 μM	-		(+)	++	++	23810
0.0005 μM	-		(+)	++	++	23810
0.0001 μM	-		(+)	++	++	23810
0.00005 μM	-		(+)	++	++	23810
CPGRA valeric acid	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
5 μM	-		-	-	+	2726
1 μM	-		-	+	++	2070
0.5 μM	-		-	+	++	3070
0.1 μM	-		-	++	++	2403
0.05 μM	-		-	++	++	2070
0.01 μM	-		(+)	++	++	5420
0.005 μM	-		(+)	++	++	13840
0.001 μM	-		(+)	++	++	9310
0.0005 μM	-		(+)	++	++	13010
0.0001 μM	-		(+)	++	++	10910
0.00005 μM	-		(+)	++	++	15650
0.00001 μM	-		(+)	++	++	16810
0.000005 μM	-		(+)	++	++	23810
0.000001 μM	-		(+)	++	++	23810
CPGRA valeric acid	Day 4	P-24 (pg/ml)	Day 5	Day 6	Day 7	P-24 (pg/ml)
5 μM	-		-	-	-	32
1 μM	-		-	-	(+)	108
0.5 μM	-		-	-	+	2000
0.1 μM	-		-	-	+	2403
0.05 μM	-		-	+	++	3810
0.01 μM	-		(+)	++	++	7810
0.005 μM	-		(+)	++	++	5600
0.001 μM	-		(+)	++	++	6400
0.0005 μM	-		(+)	++	++	3810
0.0001 μM	-		(+)	++	++	11789
0.00005 μM	-		(+)	++	++	13810
0.00001 μM	-		(+)	++	++	18710
0.000005 μM	-		(+)	++	++	23810
0.000001 μM	-		(+)	++	++	23810

Table 8 (continued)

SPC3 monomer valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-	-	-	-	-	123
1 μM	-	-	-	-	(+)	345
0.5 μM	-	-	-	(+)	(+)	1325
0.1 μM	-	-	+	++	++	4345
0.05 μM	-	-	+	++	++	11840
0.01 μM	-	-	+	++	++	12240
0.005 μM	-	-	+	++	++	11810
0.005 μM	-	-	+	++	++	15307
SPC3	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 μM	-	-	-	-	-	12
1 μM	-	-	-	-	(+)	240
0.5 μM	-	-	-	(+)	(+)	1692
0.1 μM	-	-	-	+	++	3776
0.05 μM	-	-	(+)	+	++	15173
0.01 μM	-	-	(+)	++	++	12840
0.005 μM	-	-	+	++	++	18810
0.005 μM	-	-	+	++	++	20850
0.005 μM	-	-	+	++	++/T	23810
0.005 μM	-	-	+	++	++/T	23810
0.005 μM	-	-	+	++	++/T	23810
0.005 μM	-	-	+	++	++/T	23810
TCell	-	-	-	-	-	-
NL4-3 1/1000	(+)	(+)	++	++	++/T	19657
			++	++	++/T	23810

Table 9

Antiviral Activity Experiment on C8166 cells with HIV-1 subtype B NL 4-3

Name	Formula	IC ₅₀ (μM)	IC ₁₀₀ (μM)
PGP	PGP	0.01 0.01	5 5
PGP valeric acid	PGP-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01 0.01	0.5 1
GPGR	GPGR	0.06 0.1	5 >5
GPGR valeric acid	GPGR-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.03 0.01	5 1
PGGRA	PGGRA	0.03 0.02	0.5 >5
PGGRA valeric acid	PGGRA-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.01 0.01	0.1 1
SPC3 monomer valeric acid	PGGRAF-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.05	5
SPC3	(PGGRAF) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.5	5

Table 10

Antiviral Activity Experiment on C8166 cells with HIV 1 NDK


Name	Formula	IC ₅₀ (μM)	IC ₁₀₀ (μM)
PGP	PGP	0.5	>5.
PGP valeric acid	PGP-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.02	5
GPGR	GPGR	0.5	>5
GPGR valeric acid	GPGR-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.3	>5
PGGRA	PGGRA	0.04	>5
PGGRA valeric acid	PGGRA-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	>5	5
SPC3 monomer valeric acid	PGGRAF-NHCH ₂ CH ₂ CH ₂ CH ₂ COOH	0.2	5
SPC3	(PGGRAF) ₈ -K ₄ -K ₂ -K-NHCH ₂ CH ₂ COOH	0.6	5

CLAIMS

1. A compound comprising a water soluble antiviral peptide including one of the sequences GPG and RQGY and, bonded to the C-end of the peptide, a terminator which is either (a) an ω -amino-fatty acid having from 4 to 10 carbon atoms and from 0 to 2 carbon-carbon double bonds or (b) a peptidic cell membrane penetrating agent.
2. A compound according to claim 1 in which the peptide is a multiple branch peptide construction (MBPC), each branch of which contains the peptide sequence GPG and the core of which is formed from lysine residues, and the terminator is bonded to the root lysine residue.
3. A compound according to claim 2 in which each branch of the MBPC is a peptide GPGRAF.
4. A compound according to claim 1 in which the peptide is a multiple branch peptide construction (MBPC), each branch of which contains the peptide sequence RQGY and the core of which is formed from lysine residues, and the terminator is bonded to the root lysine residue.
5. A compound according to claim 4 in which each branch of the MBPC is a peptide RQGYSPL.
6. A compound according to claim 4 in which each branch of the MBPC is a peptide RQGYS.
7. A compound according to claim 3, claim 5 or claim 6 in which the MBPC has two branches.
8. A compound according to claim 3, claim 5 or claim 6 in which the MBPC has eight branches.
9. A compound according to claim 1 in which the peptide is GPG, GPGR, GPGRA or GPGRAF.

10. A compound according to claim 1 in which the peptide is RQGYS or RQGYSPL.
11. A compound according to any preceding claim in which the terminator is an ω -amino saturated fatty acid having from 4 to 8 carbon atoms.
12. A compound according to any preceding claim in which the terminator is an ω -amino saturated fatty acid having from 4 to 6 carbon atoms.
13. A compound according to any preceding claim in which the terminator is γ -aminobutyric acid, δ -aminovaleric acid or ϵ -aminocaproic acid.
14. A compound according to any of claims 1 to 10 in which the terminator is a TAT-derived peptide, penetratin® or Kpam.

PCT/EP2004/005563



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

**IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**